The European Medicines Agency is calling for two heart conditions to be listed as side effects Nuvaxovid shot. Here's what you need to know.
The European Medicines Agency is recommending Novavax's COVID-19 vaccine carry a warning of the rare possibility it will cause two types of heart inflammation.TGA figures show about 189,200 doses of Novavax have been administered in Australia to 24 July 2022An Australian epidemiologist says "a very small number of people" have been affected
US vaccine developer Novavax said no concerns about heart inflammations were raised during the clinical trials of Nuvaxovid, and more data would be gathered. He added that the Australia's medicines regulator, the Therapeutic Goods Administration, would be well aware of the EMA’s recommendation."In reality, it's a very small number of people. This is not considered to be a major issue."oined Australia's national vaccine programTGA figures show about 189,200 doses of the Novavax shot have been administered in Australia to July 24 this year.
"As a result of our investigation, the Product Information for Nuvaxovid has been updated to include pericarditis as a potential adverse event."